- Home
- MAS vs CNTX Comparison
MAS vs CNTX Comparison
Compare MAS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- CNTX
- Stock Information
- Founded
- MAS 1929
- CNTX 2015
- Country
- MAS United States
- CNTX United States
- Employees
- MAS N/A
- CNTX N/A
- Industry
- MAS Industrial Specialties
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MAS Industrials
- CNTX Health Care
- Exchange
- MAS Nasdaq
- CNTX Nasdaq
- Market Cap
- MAS 15.9B
- CNTX 75.6M
- IPO Year
- MAS N/A
- CNTX 2021
- Fundamental
- Price
- MAS $73.64
- CNTX $0.84
- Analyst Decision
- MAS Buy
- CNTX Strong Buy
- Analyst Count
- MAS 14
- CNTX 5
- Target Price
- MAS $74.86
- CNTX $5.25
- AVG Volume (30 Days)
- MAS 2.0M
- CNTX 151.3K
- Earning Date
- MAS 10-28-2025
- CNTX 11-05-2025
- Dividend Yield
- MAS 1.68%
- CNTX N/A
- EPS Growth
- MAS N/A
- CNTX N/A
- EPS
- MAS 3.76
- CNTX N/A
- Revenue
- MAS $7,663,000,000.00
- CNTX N/A
- Revenue This Year
- MAS N/A
- CNTX N/A
- Revenue Next Year
- MAS $3.39
- CNTX N/A
- P/E Ratio
- MAS $19.59
- CNTX N/A
- Revenue Growth
- MAS N/A
- CNTX N/A
- 52 Week Low
- MAS $56.55
- CNTX $0.49
- 52 Week High
- MAS $86.70
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- MAS 53.07
- CNTX 53.79
- Support Level
- MAS $73.00
- CNTX $0.81
- Resistance Level
- MAS $75.42
- CNTX $0.89
- Average True Range (ATR)
- MAS 1.38
- CNTX 0.05
- MACD
- MAS -0.25
- CNTX -0.01
- Stochastic Oscillator
- MAS 44.32
- CNTX 25.00
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.